Award
NIH Reporter #1R43AR087150-01
Development of the novel small-molecule anti-osteoclastic drug ELP-004 to alleviate the symptoms of osteogenesis imperfecta (OI)
Recipient
EXESALIBERO, INC.
Award Amount
$172,164.00
Ceiling
$172,164.00
Awarded
August 07, 2026
Identifier
1R43AR087150-01
Award for developing ELP-004, a novel small molecule drug targeting TRPC channels to treat osteogenesis imperfecta by preventing bone erosion and inflammation, with potential to improve patient quality of life.
Description
Development of a new approach to treat bone erosion and inflammation associated with osteogenesis imperfecta (OI) by inhibiting TRPC channel activity using the small molecule ELP-004, aiming to improve treatment of Type III OI symptoms in a mouse model.